Sartorius Set to Double Glasgow Workforce in 2016
News Apr 28, 2016
Sartorius Stedim BioOutsource, a leading provider of contract testing services to the biopharmaceutical industry, is pleased to announce that it is looking to almost double the scientific workforce at its Glasgow facilities in 2016. The new staff will help to meet increasing global demand for the firm’s analytical expertise in testing a wide range of biologics-based drugs and vaccines.
BioOutsource’s facilities in Glasgow have continued to grow since its acquisition by Sartorius Stedim Biotech in 2015. One contributing factor is the expansion in the number of assays developed by BioOutsource’s scientists.
Due to its success, the firm is actively recruiting a number of post-doctoral or PhD scientists. The new staff will work in a modern bioanalytical laboratory environment in areas of large molecule drug analysis, using systems such as a Biacore.
For information on the types of roles available at BioOutsource scientists should click this link: http://ow.ly/4mW7X1
Dr Daniel Galbraith, Chief Scientific Officer of Sartorius Stedim BioOutsource stated: "We’re delighted to be recruiting new scientists because it allows us to harness the skills of the talented researchers being trained in drug discovery at the UK’s outstanding universities. This will allow us to go from strength to strength by consolidating our expertise and building niche bioanalytical skills in Glasgow.”
Galbraith continued: “Expanding our team’s expertise will provide our global pharmaceutical and biotechnology industry clients with excellent quality analytical testing, enabling them to rapidly and cost-effectively enter clinical development with their drugs and vaccines.”
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Cocaine Use Alters Gene Expression in Brain Reward CircuitsNews
A study in Biological Psychiatry investigates transcriptome-wide alterations in response to cocaine self-administration in mice.
Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development PartnershipNews
MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018